PACER-PJI: Prospective Cohort Study on Antibiotic Course and Efficacy After Two-stage Revision in PJI.

Sponsor
First Affiliated Hospital of Fujian Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05284318
Collaborator
(none)
500
1
61
8.2

Study Details

Study Description

Brief Summary

This is a multicenter prospective cohort study in which patients were evaluated by inclusion and exclusion criteria before phase II revision surgery. Eligible patients will be included in this study after signing the informed consent form. After the second stage revision, according to the patient's symptoms and examination results, the attending physician used a reasonable antibiotic treatment scheme (including intravenous and oral medication). All patients voluntarily participated in the study and signed informed consent. During the treatment period, all prospective patients underwent clinical evaluation at the time points of 1, 3, 6, 12, 18 and 24 months after the start of antibiotic treatment after phase II revision. The infection control rate of patients was evaluated by follow-up at least 2 years after operation, so as to analyze the effect of antibiotic treatment course after two-stage revision of periprosthetic joint infection.

Condition or Disease Intervention/Treatment Phase
  • Drug: Antibiotics treatment

Detailed Description

Inclusion criteria:

  1. A diagnosis of PJI was made according to MSIS criteria

  2. Received spacer implantation and a full course of antibiotic treatment (at least 6 weeks), the patient was clinically determined to have infection control and underwent secondary joint revision.

  3. Age ≥18 years old

  4. The patient voluntarily participated in the study, and was physically and mentally tolerant to the treatment process and various tests of the study. He has signed an informed consent form and passed the examination of all the hospital ethics committees participating in the study.

Exclusion criteria:

  1. Follow up data were not available;

  2. The investigator judged that the patient no longer met the criteria of the study due to compliance problems.

Recruiting time:2021.10 -2023.10.31 Interventions Group:No Sample size:500 Study Population Description: Patients who underwent secondary replantation surgery for prosthetic joint infection at the First Affiliated Hospital of Fujian Medical University and other sub-centers were selected.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
500 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Effect of Antibiotic Treatment Course on Clinical Outcome After Two-stage Revision of Prosthetic Joint Infection: A Prospective Cohort Study.
Actual Study Start Date :
Dec 1, 2021
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2026

Outcome Measures

Primary Outcome Measures

  1. Clearance rate of infection [31, December,2026]

    Number of subjects with infection cleared/total number of subjects who completed follow-up

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
    1. A diagnosis of PJI was made according to MSIS criteria. 2. Received spacer implantation and a full course of antibiotic treatment (at least 6 weeks), the patient was clinically determined to have infection control and underwent secondary joint revision.
  1. Age ≥18 years old. 4. The patient voluntarily participated in the study, and was physically and mentally tolerant to the treatment process and various tests of the study. He has signed an informed consent form and passed the examination of all the hospital ethics committees participating in the study.
Exclusion Criteria:
    1. Follow-up data not available. 2. Researchers judge that patients no longer meet the standards of the study due to compliance problems

Contacts and Locations

Locations

Site City State Country Postal Code
1 The First Affiliated Hospital of Fujian Medical University Fuzhou Fujian China

Sponsors and Collaborators

  • First Affiliated Hospital of Fujian Medical University

Investigators

  • Study Director: Zhang, Director, First Affiliated Hospital of Fujian Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Xinyu Fang, Deputy chief physician, First Affiliated Hospital of Fujian Medical University
ClinicalTrials.gov Identifier:
NCT05284318
Other Study ID Numbers:
  • MRCTA ECFAH of FMU 2021404
First Posted:
Mar 17, 2022
Last Update Posted:
Mar 17, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Xinyu Fang, Deputy chief physician, First Affiliated Hospital of Fujian Medical University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 17, 2022